No Data
[Brokerage Focus] Softbank China gives a strong Buy rating to Chuangsheng Group (06628), indicating that its potential value is underestimated by the market.
Jinwu Financial News | Softbank China Research indicates that Chuangsheng Group (06628) has an experienced and comprehensive team, with Global clinical research and development capabilities in China and the USA. They employ a multi-regional development Global Strategy, utilizing proprietary antibody discovery platforms, integrated CMC capabilities, advanced translational science platforms, and HiCB manufacturing technology to advance innovations in drugs for various diseases, while also providing CDMO services to generate revenue. The company's core product Osemitamab (TST001) is a potentially best-in-class humanized antibody targeting Claudin18.2 (CLDN18.2).
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
On January 14, TRANSCENTA-B (06628) spent 0.0244 million Hong Kong dollars to repurchase 0.0405 million shares.
TRANSCENTA-B (06628) announced that on January 14, 2025, the company invested 0.0244 million Hong Kong dollars...
TRANSCENTA-B (06628.HK) repurchased 0.01 million shares on January 10.
Gelonghui January 10th丨TRANSCENTA-B (06628.HK) announced that on January 10th, it spent HKD 6,100 to repurchase 0.01 million shares.
TRANSCENTA-B (06628.HK) spent 0.06 million HKD to repurchase 0.1 million shares on January 9.
On January 9, Legend Holdings Group-B (06628.HK) announced that it spent 0.06 million Hong Kong dollars to repurchase 0.1 million shares.
TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.
Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.
